Osimertinib, platinum, and etoposide for patients with metastatic EGFR / TP53 / RB1 -mutant lung cancers at risk for histological transformation
Year: 2026
Type: article
Source: Science Translational Medicine
Authors: Lena Morrill Gavarró, Monica F. Chen, Álvaro Quintanal Villalonga, Yufei Deng, Liancheng Lu, Britney Forsyth, Sahil Sahni, Eric G. Sun, Swanand Rakhade, Rania G. Aly, Meng Wang, Amin Sabet, Prithviraj Solanki, Christina Wilson, Natasha Rekhtman, Sam Tischfield, Jake June-Koo Lee, Khadeja Moses, Linda Ahn, Clare Wilhelm, Amanda Pupo, Christina Falcon, Andrea Arfe, Katherine Panageas, Mark G. Kris, Parvathy Manoj, Ignas Masilionis, Ojasvi Chaudhary, Ronan Chaligne, Esther Redin, Eric Gardner, Xinjun Wang, Dana Pe’er, Charles M. Rudin, Joseph M. Chan, Helena A. Yu
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7225823918